SCHEMBL18148050

SCHEMBL18148050

CNC(=O)C=Cc1c(NS(=O)(=O)c2cccs2)cc2c(c1F)NCN2C

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CNKSR1 Q969H4 12/20 0.51
AKT1 P31749 4/20 0.40
HDAC1 Q13547 1/20 0.40
CCR2 P41597 1/20 0.39
TP53 P04637 1/20 0.38
BRD4 O60885 1/20 0.37
PKM P14618 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
HPGD P15428 1/20 0.36
PTGER3 P43115 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18148048 1.00 CNKSR1 (0.51) CNKSR1AKT1HDAC1CCR2TP53
SCHEMBL18148205 0.88 CNKSR1 (0.62) CNKSR1AKT1HDAC1TP53PTGER3
SCHEMBL18148208 0.88 CNKSR1 (0.62) CNKSR1AKT1HDAC1TP53PTGER3
SCHEMBL18148035 0.79 CNKSR1 (0.51) CNKSR1AKT1TP53
SCHEMBL18148038 0.79 CNKSR1 (0.51) CNKSR1AKT1TP53
SCHEMBL18160912 0.76 CNKSR1 (0.64) CNKSR1AKT1MEN1MAPTKMT2A
SCHEMBL18148029 0.72 CNKSR1 (0.39) CNKSR1CCR2MAPTHPGD
SCHEMBL18148034 0.72 CNKSR1 (0.39) CNKSR1CCR2MAPTHPGD
SCHEMBL18148082 0.67 CNKSR1 (0.51) CNKSR1AKT1HDAC1CCR2TP53
SCHEMBL18148080 0.67 CNKSR1 (0.51) CNKSR1AKT1HDAC1CCR2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2019-03-12 US disclosed
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2019-03-12 US disclosed
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-20 US disclosed
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 CNKSR1, CAMKK1, CNR1 CNKSR1 1/4885AKT1 780/4885HDAC1 1619/4885
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 CNKSR1, CAMKK1, CNR1 CNKSR1 1/4885AKT1 780/4885HDAC1 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.